product name Perindopril Erbumine
Description: Perindopril Erbumine (also called S9490-3) is a potent ACE inhibitor with IC50 of 1.05 nM. It is a brain penetrant. and can suppress the increase in hippocampal ACE activity and improves cognition in PS2APP-transgenic mice. Perindopril Erbumine displays a higher binding affinity for the bradykinin binding sites than the angiotensin I binding sites of ACE. Perindopril Erbumine inhibits the angiotensin- and Aβ42-to-Aβ40-converting activity of mutated ACE containing two active domains (F-ACE) with IC50 of 0.03-0.1 μM, and 0.01-0.03 μM, respectively.
References: Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6; J Biol Chem. 2009 Nov 13;284(46):31914-20.
441.6
Formula
C19H32N2O5.C4H11N
CAS No.
107133-36-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 88 mg/mL (199.3 mM)
Ethanol: 88 mg/mL (199.3 mM)
Solubility (In vivo)
Saline: 30 mg/mL
Synonyms
S9490-3
other peoduct :
| In Vitro |
In vitro activity: Perindopril Erbumine displays a higher binding affinity for the bradykinin binding sites than the angiotensin I binding sites of the angiotensin-converting enzyme (ACE) with bradykinin/angiotensin I selectivity ratio of 1.44. Perindopril Erbumine inhibits the angiotensin- and Aβ42-to-Aβ40-converting activity of mutated ACE containing two active domains (F-ACE) with IC50 of 0.03-0.1 μM, and 0.01-0.03 μM, respectively. Perindopril Erbumine (~2 μM) displays no significant cytotoxicity towards SCC-VII and KB cells, but can significantly reduce the production of angiotensin II and the transcription of VEGF in KB cells in a concentration-dependent manner. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Oral administration of Perindopril Erbumine at 2 mg/kg/day has a significant inhibitory effect on SCC-VII tumor growth, and reduces blood vessel formation surrounding the tumors in vivo due to the suppression of VEGF-induced angiogenesis. Administration of Perindopril Erbumine at 2 mg/kg/day displays a strong inhibitory effect of the BNL-HCC tumor growth in rats similar to that of 20 mg/kg/day and in contrast to the AT1-R antagonist candesartan or losartan which at the dose of 20 mg/kg/day has no inhibitory effect. Administration of Perindopril Erbumine at 3 mg/kg/day significantly inhibits LPS-induced apoptosis by 6.4% in RAECs in vivo than that of ramipril by 3.2%. Administration of Perindopril Erbumine (1 mg/kg/day) significantly suppresses the hippocampal ACE activity, and prevents cognitive impairment and brain injury in rats with Alzheimers disease (AD). |
| Animal model | Female BALB/c nude mice injected with SCC-VII cells |
| Formulation & Dosage | Dissolved in DMSO, and diluted in saline; 1 or 2 mg/kg/day; p.o. |
| References | Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6; J Biol Chem. 2009 Nov 13;284(46):31914-20; J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73. |
